Bratislavské lekárske listy/Bratislava medical journal · 2017 · 23 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyMalignant NeoplasmsOncology PharmacologyAnticancer ActivityAnticancer Natural ProductsCancer Cell Proliferation InhibitionCell Proliferation IndicesNucleolar OrganizationNucleolar Organizer RegionsPositive Control SelectionSublethal Dose Selection
BACKGROUND: Rhamnetin is a flavonoid that has antioxidant, anti-inflammatory and anti-cancer effects. Nucleolar-organizing regions are the ribosomal genes region. We aimed to identify whether rhamnetin has an effect on cell proliferation and whether AgNOR proteins may be used for the detection of therapeutic benefits of the drugs and new metabolites, which have the potential of being used for cancer treatments. METHODS: Twenty-four mice with Ehrlich's ascites carcinoma (EAC) were randomly assigned to three main groups as positive control, and groups 2 and 3 treated intraperitoneally with rhamnetin (100 µg/kg and 200 µg/kg, respectively). All the animals were sacrificed on day16, 24 h after the last dose; the tumors, which developed at the site of injection were removed. Then, mean AgNOR number and total AgNOR area/nuclear area (TAA/NA) were detected for each mouse. RESULTS: Significant differences were detected among all groups for mean AgNOR number (p = 0.000) and TAA/NA ratio (p = 0.000). While the difference between positive control and Rhamnetin (100 µg/kg) group was not significant (p = 0.387), there are significant differences between positive control and Rhamnetin (200 µg/kg) group (p = 0.000) and between Rhamnetin (100 µg/kg) and Rhamnetin (200 µg/kg) groups (p = 0.000) for TAA/NA ratio. CONCLUSION: Rhamnetin has an important role in preventing cancer formation. Our study showed that mean AgNOR numbers and TAA/NA values may be used also as biomarkers for evaluating the success rate of the performed therapeutic strategy and accurate dose selection for the management of the disease (Tab. 3, Fig. 3, Ref. 45).
24
Beta‐carotene, carotenoids, and disease prevention in humans
Susan T. Mayne · The FASEB Journal · 1996 · 854 citations
miR-34 – a microRNA replacement therapy is headed to the clinic
Andreas G. Bader · Frontiers in Genetics · 2012 · 725 citations · Full text
Medicine, Cancer Biology, Oncology +17
Tomohiro Sawa, Mayumi Nakao, Takaaki Akaike et al. · Journal of Agricultural and Food Chemistry · 1998 · 359 citations
Medicine, Cancer Biology, Oncology +17
The New Era in Cancer Research
Harold Varmus · Science · 2006 · 306 citations
Medicine, Cancer Biology, Oncology +11